Literature DB >> 16647717

Crystallographic and pre-steady-state kinetics studies on binding of NADH to wild-type and isoniazid-resistant enoyl-ACP(CoA) reductase enzymes from Mycobacterium tuberculosis.

Jaim S Oliveira1, José H Pereira, Fernanda Canduri, Nathália C Rodrigues, Osmar N de Souza, Walter F de Azevedo, Luiz A Basso, Diógenes S Santos.   

Abstract

An understanding of isoniazid (INH) drug resistance mechanism in Mycobacterium tuberculosis should provide significant insight for the development of newer anti-tubercular agents able to control INH-resistant tuberculosis (TB). The inhA-encoded 2-trans enoyl-acyl carrier protein reductase enzyme (InhA) has been shown through biochemical and genetic studies to be the primary target for INH. In agreement with these results, mutations in the inhA structural gene have been found in INH-resistant clinical isolates of M.tuberculosis, the causative agent of TB. In addition, the InhA mutants were shown to have higher dissociation constant values for NADH and lower values for the apparent first-order rate constant for INH inactivation as compared to wild-type InhA. Here, in trying to identify structural changes between wild-type and INH-resistant InhA enzymes, we have solved the crystal structures of wild-type and of S94A, I47T and I21V InhA proteins in complex with NADH to resolutions of, respectively, 2.3A, 2.2A, 2.0 A, and 1.9A. The more prominent structural differences are located in, and appear to indirectly affect, the dinucleotide binding loop structure. Moreover, studies on pre-steady-state kinetics of NADH binding have been carried out. The results showed that the limiting rate constant values for NADH dissociation from the InhA-NADH binary complexes (k(off)) were eleven, five, and tenfold higher for, respectively, I21V, I47T, and S94A INH-resistant mutants of InhA as compared to INH-sensitive wild-type InhA. Accordingly, these results are proposed to be able to account for the reduction in affinity for NADH for the INH-resistant InhA enzymes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16647717     DOI: 10.1016/j.jmb.2006.03.055

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  18 in total

1.  Conformational changes in 2-trans-enoyl-ACP (CoA) reductase (InhA) from M. tuberculosis induced by an inorganic complex: a molecular dynamics simulation study.

Authors:  André L P da Costa; Ivani Pauli; Márcio Dorn; Evelyn K Schroeder; Chang-Guo Zhan; Osmar Norberto de Souza
Journal:  J Mol Model       Date:  2011-08-12       Impact factor: 1.810

2.  Computational structural analysis of proteins of Mycobacterium tuberculosis and a resource for identifying off-targets.

Authors:  Sameer Hassan; Abhimita Debnath; Vasantha Mahalingam; Luke Elizabeth Hanna
Journal:  J Mol Model       Date:  2012-04-27       Impact factor: 1.810

3.  Crystal structures and kinetic properties of enoyl-acyl carrier protein reductase I from Candidatus Liberibacter asiaticus.

Authors:  Ling Jiang; Zengqiang Gao; Yanhua Li; Shennan Wang; Yuhui Dong
Journal:  Protein Sci       Date:  2014-02-12       Impact factor: 6.725

4.  A virtual screen discovers novel, fragment-sized inhibitors of Mycobacterium tuberculosis InhA.

Authors:  Alexander L Perryman; Weixuan Yu; Xin Wang; Sean Ekins; Stefano Forli; Shao-Gang Li; Joel S Freundlich; Peter J Tonge; Arthur J Olson
Journal:  J Chem Inf Model       Date:  2015-02-17       Impact factor: 4.956

Review 5.  Protein targets for structure-based anti-Mycobacterium tuberculosis drug discovery.

Authors:  Zhiyong Lou; Xiaoxue Zhang
Journal:  Protein Cell       Date:  2010-06-04       Impact factor: 14.870

Review 6.  Winning the arms race by improving drug discovery against mutating targets.

Authors:  Amy C Anderson
Journal:  ACS Chem Biol       Date:  2011-11-11       Impact factor: 5.100

7.  Large cosolutes, small cosolutes, and dihydrofolate reductase activity.

Authors:  Luis C Acosta; Gerardo M Perez Goncalves; Gary J Pielak; Annelise H Gorensek-Benitez
Journal:  Protein Sci       Date:  2017-11-17       Impact factor: 6.725

8.  Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance.

Authors:  Florence Brossier; Nicolas Veziris; Chantal Truffot-Pernot; Vincent Jarlier; Wladimir Sougakoff
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

9.  Mechanisms of resistance against NITD-916, a direct inhibitor of Mycobacterium tuberculosis InhA.

Authors:  Matthew B McNeil; Devon Dennison; Catherine Shelton; Lindsay Flint; Aaron Korkegian; Tanya Parish
Journal:  Tuberculosis (Edinb)       Date:  2017-09-13       Impact factor: 3.131

10.  Towards a new tuberculosis drug: pyridomycin - nature's isoniazid.

Authors:  Ruben C Hartkoorn; Claudia Sala; João Neres; Florence Pojer; Sophie Magnet; Raju Mukherjee; Swapna Uplekar; Stefanie Boy-Röttger; Karl-Heinz Altmann; Stewart T Cole
Journal:  EMBO Mol Med       Date:  2012-09-17       Impact factor: 12.137

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.